Brazil rejects Viread patent application
This article was originally published in Scrip
Executive Summary
Brazil's patent office, the INPI, has issued a final rejection of Gilead Sciences' patent application for its antiretroviral Viread (tenofovir disoproxil). And if the office rejects a divisional patent application for the same drug, Brazil could soon access generic versions of Viread.